Betashares Strong Australian Dollar Fund (AUDS)

Overview

MedMira Inc. is a prominent biotechnology firm deeply engaged in the research, development, manufacturing, and commercialization of rapid diagnostics and technological platforms that span across North America, Europe, the Asia Pacific, and other international markets. Established in 1993 with its headquarters nestled in Halifax, Canada, MedMira operates as a key subsidiary of MedMira Holding AG. The company serves an extensive customer base in the healthcare industry, including laboratories, hospitals, point-of-care clinics, governments, aid organizations, and public health agencies, leveraging a network of medical distributors and strategic business development partners for product sales. MedMira specializes in crafting innovative solutions for the swift diagnosis of various infectious diseases, standing at the forefront of addressing global health challenges with its state-of-the-art diagnostic tests.

Products and Services

• Reveal HIV - A rapid diagnostic test capable of detecting antibodies to both HIV-1 and HIV-2 in whole blood, serum, or plasma, helping facilitate early and accurate diagnosis of HIV.
• Reveal TP - This syphilis antibody test quickly detects treponema pallidum antibodies in serum, plasma, or whole blood, aiding in the rapid diagnosis of syphilis infections.
• Multiplo - The Multiplo product line encompasses multiplex tests that offer combination testing solutions for HIV-1/2, Hepatitis B and C, and syphilis. These tests empower healthcare providers with the ability to conduct comprehensive screenings for multiple infectious diseases simultaneously.
• Miriad Triple Product - Designed for preliminary screening of HIV and hepatitis, this product underscores MedMira’s commitment to facilitating early detection and intervention for these life-threatening conditions.
• Miriad RVF Toolkit - A dynamic toolkit designed to support the development and commercialization of rapid diagnostics, highlighting MedMira’s dedication to advancing diagnostic technologies and solutions.
• Reveal G4 HIV Tests - The latest addition to MedMira’s HIV diagnostic products, offering enhanced sensitivity and specificity for HIV detection in various biological samples.
• VYRATM TriDemic Antigen Rapid Test - A groundbreaking rapid test capable of distinguishing between three respiratory viruses: SARS-CoV-2, influenza, and respiratory syncytial virus. Given their symptom similarities, this test provides crucial diagnostic clarity, aiding in appropriate disease management and containment efforts.